Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.39 |
| ▸ | IL4I1 | Q96RQ9 | 1/20 | 0.36 |
| ▸ | NOTUM | Q6P988 | 3/20 | 0.33 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.32 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.32 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.31 |
| ▸ | USP1 | O94782 | 2/20 | 0.30 |
| ▸ | MAOA | P21397 | 1/20 | 0.30 |
| ▸ | HTR2A | P28223 | 1/20 | 0.30 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30947936 | 0.86 | IL4I1 (0.38) | IL4I1HCRTR1HCRTR2USP1 | |
| SCHEMBL30948347 | 0.84 | IL4I1 (0.39) | DYRK1AIL4I1 | |
| SCHEMBL30948389 | 0.83 | IL4I1 (0.43) | IL4I1 | |
| SCHEMBL30947905 | 0.80 | CHRM1 (0.49) | GSK3BDYRK1AIL4I1HCRTR1HCRTR2 | |
| SCHEMBL30948022 | 0.78 | GSK3B (0.35) | GSK3BDYRK1AIL4I1NOTUMCYP19A1 | |
| SCHEMBL30948260 | 0.76 | IL4I1 (0.46) | IL4I1HCRTR1HCRTR2 | |
| SCHEMBL30948108 | 0.71 | IL4I1 (0.41) | IL4I1HCRTR2 | |
| SCHEMBL30948172 | 0.70 | IL4I1 (0.54) | DYRK1AIL4I1HCRTR1HCRTR2 | |
| SCHEMBL30948051 | 0.69 | IL4I1 (0.59) | IL4I1 | |
| SCHEMBL30947928 | 0.69 | IL4I1 (0.60) | IL4I1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240246937-A1 | IL4I1 INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2024-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240246937-A1 | IL4I1 INHIBITORS AND METHODS OF USE | IL4I1, IL4, IL2 | GSK3B 3952/4885DYRK1A 4315/4885IL4I1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.